Eupraxia Pharmaceuticals is trading 10.57% higher at $9.00 after Stifel reiterated a Buy rating and $25.00 price target on September 24, 2026, ahead of interim Phase 2b RESOLVE data. - Stifel cited EP-104GI’s potential in eosinophilic esophagitis and positive clinical durability data. - Wedbush initiated coverage with an Outperform rating and a $17.00 target. - Broader markets were weaker, so the pre-market gain appears primarily company-specific. No trading-volume figure was provided.